Related Experiment Video
Updated: Aug 16, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
iStent Inject Implantation for Pseudoexfoliative Glaucoma. A Scoping Review
Summary
Standalone iStent inject implantation significantly reduced intraocular pressure in pseudoexfoliative glaucoma patients. This minimally invasive glaucoma surgery offers a promising alternative for managing elevated eye pressure.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Surgical Innovation
Background:
- Pseudoexfoliative (PEX) glaucoma is a subtype of open-angle glaucoma.
- Effective management of intraocular pressure (IOP) is crucial in PEX glaucoma.
- Standalone iStent inject implantation is an emerging treatment option.
Purpose of the Study:
- To assess the efficacy of standalone iStent inject implantation in PEX glaucoma patients.
- To evaluate the impact on intraocular pressure and medication burden.
- To compare findings with general open-angle glaucoma data.
Main Methods:
- A comprehensive literature search was performed across multiple databases.
- A scoping review approach was adopted due to limited studies.
- One study focusing on PEX glaucoma and a meta-analysis for comparison were included.
Main Results:
- The single included study involved 15 eyes with PEX glaucoma over a 6-month follow-up.
- Intraocular pressure decreased by 35%, from 23.75 mmHg to 15.33 mmHg.
- Further analysis is needed to fully understand the medication burden reduction.
Conclusions:
- Standalone iStent inject implantation demonstrates significant IOP reduction in PEX glaucoma.
- This procedure shows potential as a standalone treatment for PEX glaucoma.
- More research is warranted to confirm long-term outcomes and compare with other glaucoma surgeries.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...